https://www.selleckchem.com/products/Y-27632.html
tine clinical practice, 27.1% were eligible for the VOYAGER PAD trial. These patients were older, had more severe vascular symptoms, higher bleeding risk, and worse prognosis than trial participants. Among patients in routine clinical practice, 27.1% were eligible for the VOYAGER PAD trial. These patients were older, had more severe vascular symptoms, higher bleeding risk, and worse prognosis than trial participants. To evaluate the efficacy of thoracic endovascular aortic repair (TEVAR) in the treatment of patients with complicated typ
Like
Comment
Share
